Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)

Authors, Journal, Affiliations, Type, DOI

• First author / Lead: Paulus Kirchhof, MD (University Heart and Vascular Center, Hamburg)
• Co-authors: A.J. Camm, A. Goette, A. Brandes, L. Eckardt, et al. for the EAST-AFNET 4 Trial Investigators
• Affiliations: 135 centers across 11 European countries; trial planned by AFNET and the European Heart Rhythm Association
• Journal: New England Journal of Medicine. 2020;383:1305–1316
• Type: International, investigator-initiated, parallel-group, randomized, open, blinded-outcome-assessment trial (PROBE design)
• DOI: 10.1056/NEJMoa2019422

Overview

EAST-AFNET 4 is the landmark randomized trial demonstrating that early rhythm-control therapy in patients with recently diagnosed atrial fibrillation (≤1 year) and cardiovascular conditions reduces major adverse cardiovascular events compared to usual care. Across 2789 patients and a median follow-up of 5.1 years, early rhythm control reduced the composite primary outcome (CV death, stroke, or hospitalization for HF/ACS) by 21% (HR 0.79, P=0.005), with a 1.1/100 person-year absolute risk reduction. The trial was stopped early for efficacy. The benefit was independent of symptom status, including asymptomatic patients, and did not require AF-free maintenance — it was strategy-level superiority. This result directly underpins Class IIa/B-R recommendations for early rhythm control in both AHA 2023 and ESC 2024 guidelines.

Keywords

Early atrial fibrillation; rhythm control; rate control; antiarrhythmic drugs; catheter ablation; cardiovascular outcomes; stroke prevention; early intervention; AFNET; cardiovascular death

Key Takeaways

Trial Design and Population

• Design: International parallel-group RCT (PROBE design); open label, blinded outcome assessment; stopped early for efficacy at third interim analysis
• Population: 2789 adults with AF diagnosed ≤12 months before enrollment and ≥1 of the following: age >75, prior TIA/stroke, or ≥2 of
• Baseline characteristics: Median 36 days since AF diagnosis; 54% in sinus rhythm at baseline; 38% first episode, 36% paroxysmal, 26% persistent; mean CHA₂DS₂-VASc 3.4; 28.4% with stable HF; 88% hypertension; 91% on OAC at baseline
• Duration: Median 5.1 years follow-up; trial halted for efficacy (third interim analysis)
• Sites: 135 centers in 11 European countries (July 2011–December 2016)

Intervention vs. Control

• Early rhythm control (n=1395): Antiarrhythmic drugs (initially flecainide most common, later propafenone, dronedarone, amiodarone) and/or catheter ablation initiated early after randomization; cardioversion of persistent AF; ECG monitoring twice weekly with triggered escalation visits; at 2 years, 65.1% still on active rhythm-control therapy (19.4% on ablation, rest on AADs)
• Usual care (n=1394): Rate control without rhythm control unless needed for uncontrolled AF-related symptoms; at 2 years, 85.4% still managed without rhythm-control therapy

Primary Outcomes

• First primary outcome (composite of CV death, stroke, HF hospitalization, ACS hospitalization):
  • Early rhythm control: 3.9/100 person-years
  • Usual care: 5.0/100 person-years
  • HR 0.79 (96% CI 0.66–0.94; P=0.005) — absolute difference 1.1/100 person-years
• Second primary outcome (nights in hospital/year): 5.8 vs. 5.1 days/year — no significant difference (P=0.23)
• Consistent benefit across all pre-specified subgroups including asymptomatic patients, patients with or without HF, patients with obesity

Component Outcomes

• CV death: HR 0.72 (95% CI 0.52–0.98)
• Stroke: HR 0.65 (95% CI 0.44–0.97) — fewer strokes despite both groups on anticoagulation
• HF hospitalization: HR 0.81 (95% CI 0.65–1.02) — directionally consistent, NS
• ACS hospitalization: HR 0.83 (95% CI 0.58–1.19) — directionally consistent, NS

Safety

• Primary composite safety outcome (death, stroke, or rhythm-control therapy-related serious adverse events): similar between groups (231 [16.6%] vs. 223 [16.0%])
• Rhythm-control-related serious adverse events: 4.9% (early RC) vs. 1.4% (usual care) — significant (P<0.001); included pericardial tamponade, drug-induced bradycardia, AV block, torsades de pointes
• Stroke less frequent in early RC group (2.9% vs. 4.4%; P=0.03)

Secondary Outcomes

• Sinus rhythm at 2 years: 82.1% (early RC) vs. 60.5% (usual care)
• LV ejection fraction change: +1.5% vs. +0.8% — no significant difference
• QoL (EQ-5D): no significant difference between groups
• AF-related symptoms (EHRA): no significant difference; >70% asymptomatic in both groups at 1–2 years
• Cognitive function (MoCA): no significant difference

Key Interpretation Points

• Benefit was a strategy effect, not a sinus rhythm maintenance effect — at 2 years, 18% of early RC patients were not receiving rhythm control, and 15% of usual care patients had crossed over to rhythm control
• Trial was conducted before catheter ablation became a first-line option; ablation used in only 8% initially (increasing to 19.4% at 2 years) — majority benefit from AADs
• Previous landmark trials (AFFIRM, RACE) enrolled patients with established, long-standing AF → no benefit of rhythm control; EAST-AFNET 4 enrolled early AF → significant benefit
• The comparable QoL despite significant CV outcome benefit suggests the mechanism is beyond symptom relief — possibly via atrial remodeling prevention, reduced AF burden, or stroke risk reduction
• Dronedarone's superiority in ATHENA (mostly early AF, 75% in sinus rhythm at enrollment) vs. harm in PALLAS (chronic permanent AF) aligns with the early intervention hypothesis

Limitations of the document

• Open-label design (blinded outcome assessment only) — potential for treatment selection bias
• Not designed to assess superiority of specific rhythm-control strategies (AADs vs. ablation)
• Enrolled only patients with early AF and cardiovascular conditions — results may not generalize to late AF or low-risk patients
• No detailed AF burden data collected in either arm — percent-time in AF unknown
• Ablation use was low (~8% initially); more contemporary practice with upfront ablation may yield even greater benefit
• Most symptomatic patients may have been excluded (eligible for either strategy, per protocol)
• European-only trial — potential differences in healthcare systems and treatment access
• Stopping early for efficacy may slightly overestimate true treatment effect size

Key Concepts Mentioned

• concepts/Catheter-Ablation-AF — used as part of early rhythm control strategy
• concepts/AF-Staging — early AF (diagnosed ≤1 year) is the target population
• concepts/CHA2DS2-VA — mean score 3.4; all patients on OAC regardless of arm

Key Entities Mentioned

• entities/Atrial-Fibrillation — core trial entity; establishes strategy superiority of early rhythm control
• entities/DCM — some HF patients enrolled (LVEF <50%); HF hospitalization component

Wiki Pages Updated

• wiki/sources/EAST-AFNET4-NEJM-2020.md — created
• wiki/entities/Atrial-Fibrillation.md — updated (source_count 4→5; EAST-AFNET 4 data added)
• wiki/concepts/Catheter-Ablation-AF.md — updated (source_count 2→3; EAST-AFNET 4 context added)
• wiki/concepts/AF-Staging.md — updated (source_count 1→2; early AF concept linked)
• wiki/index.md — updated
• wiki/log.md — updated